Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere Seeks to Raise $30.6M in Public Stock Offering

NEW YORK (GenomeWeb News) – Nanosphere on Friday said that it had filed to offer 4.7 million shares of its common stock in a public offering.

The Northbrook, Ill.-based molecular diagnostics firm priced the offering at $7 per share and expects net proceeds of $30.6 million from the offering — or $35.3 million if the over-allotment option of 705,000 shares is exercised. Nanosphere's shares closed Thursday unchanged at $7.65 on the Nasdaq.

Nanosphere did not specify its intended use of proceeds, other than saying such funds would be applied to general corporate purposes and working capital.

The firm sells the Verigene System, a molecular diagnostics platform that received US Food and Drug Administration clearance in 2007. The company also holds FDA clearance for a variety of assays for hypercoagulation, warfarin metabolism, and cystic fibrosis, as well as a respiratory virus panel.

Nanosphere also has filed for FDA clearance of a hemochromatosis assay and expects to file for clearance of a protein test for cardiac troponin I by the end of this year.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.